Summary
5.25 -0.19(-3.49%)05/17/2024
Affimed N.V. (AFMD)
Affimed N.V. (AFMD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.29 | -3.14 | -9.95 | 789.83 | 1,550.94 | 476.92 | 48.31 | -7.89 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.25 | |
| Open | 5.13 | |
| High | 5.33 | |
| Low | 5.11 | |
| Volume | 34,730 | |
| Change | 0.02 | |
| Change % | 0.29 | |
| Avg Volume (20 Days) | 58,160 | |
| Volume/Avg Volume (20 Days) Ratio | 0.60 | |
| 52 Week Range | 0.22 - 7.24 | |
| Price vs 52 Week High | -27.49% | |
| Price vs 52 Week Low | 2,286.36% | |
| Range | 2.42 | |
| Gap Up/Down | -0.15 | |
Fundamentals | ||
| Market Capitalization (Mln) | 80 | |
| EBIDTA | -102,586,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 22.94 | |
| Book Value | 3.8540 | |
| Earnings Per Share | -7.6200 | |
| EPS Estimate Current Quarter | -1.6700 | |
| EPS Estimate Next Quarter | -1.4400 | |
| EPS Estimate Current Year | -5.0000 | |
| EPS Estimate Next Year | -4.0100 | |
| Diluted EPS (TTM) | -7.6200 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -3.8246 | |
| Return on asset (TTM) | -0.4350 | |
| Return on equity (TTM) | -1.0055 | |
| Revenue TTM | 13,914,000 | |
| Revenue per share TTM | 0.9310 | |
| Quarterly Revenue Growth (YOY) | -0.5830 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 42,869,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.4102 | |
| Revenue Enterprise Value | 3.6400 | |
| EBITDA Enterprise Value | -0.2942 | |
| Shares | ||
| Shares Outstanding | 15,227,500 | |
| Shares Float | 13,499,146 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 6.01 | |
| Institutions (%) | 35.75 | |
05/17 15:55 EST - investorplace.com
Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
Many analysts forecast that an interest rate cut is coming by September. When that happens, speculative capital is likely to move away from large-cap stocks.
Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
Many analysts forecast that an interest rate cut is coming by September. When that happens, speculative capital is likely to move away from large-cap stocks.
05/14 10:05 EST - globenewswire.com
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of an abstract for the annual congress of the European Hematology Association (EHA), taking place in Madrid, Spain, June 13 – 16, 2024. The abstract presents preclinical data of Affimed's CD16A/CD123-targeting ICE®, AFM28, in an acute myeloid leukemia (AML) mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls.
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of an abstract for the annual congress of the European Hematology Association (EHA), taking place in Madrid, Spain, June 13 – 16, 2024. The abstract presents preclinical data of Affimed's CD16A/CD123-targeting ICE®, AFM28, in an acute myeloid leukemia (AML) mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls.
04/24 10:56 EST - zacks.com
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
04/24 04:05 EST - globenewswire.com
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager (ICE®), in combination with atezolizumab, Roche's checkpoint inhibitor, in patients with EGFR-wildtype (EGFRwt) non-small cell lung cancer (NSCLC) has been accepted for poster presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager (ICE®), in combination with atezolizumab, Roche's checkpoint inhibitor, in patients with EGFR-wildtype (EGFRwt) non-small cell lung cancer (NSCLC) has been accepted for poster presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
04/17 10:55 EST - zacks.com
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Affimed N.V. (AFMD), indicating that the stock has found support.
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Affimed N.V. (AFMD), indicating that the stock has found support.
04/04 10:56 EST - zacks.com
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
The consensus price target hints at a 263.4% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
The consensus price target hints at a 263.4% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
03/28 12:04 EST - seekingalpha.com
Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
03/28 06:30 EST - globenewswire.com
Affimed Reports 2023 Financial Results and Operational Progress
MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.
Affimed Reports 2023 Financial Results and Operational Progress
MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.
03/21 06:30 EST - globenewswire.com
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.
03/14 13:01 EST - zacks.com
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
03/08 08:37 EST - investorplace.com
Why Is Affimed (AFMD) Stock Moving Today?
Affimed (NASDAQ: AFMD ) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company's shares to undergo a reverse split later today. AFMD stock will go through a one-for-10 reverse stock split after markets close today.
Why Is Affimed (AFMD) Stock Moving Today?
Affimed (NASDAQ: AFMD ) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company's shares to undergo a reverse split later today. AFMD stock will go through a one-for-10 reverse stock split after markets close today.
03/06 15:36 EST - investorplace.com
7 of the Best Speculative Stocks You Can Snag for Less Than $1
I'm about to drop a truth bomb about speculative stocks under $1. Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana?
7 of the Best Speculative Stocks You Can Snag for Less Than $1
I'm about to drop a truth bomb about speculative stocks under $1. Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana?
03/06 06:30 EST - globenewswire.com
Affimed Announces 1-for-10 Reverse Stock Split
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior approval of the Company's supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 (“Common Shares”) per share.
Affimed Announces 1-for-10 Reverse Stock Split
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior approval of the Company's supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 (“Common Shares”) per share.
01/08 16:05 EST - globenewswire.com
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an update on the clinical response data for the ongoing AFM24-102 phase 1/2a study in EGFRwt NSCLC.
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an update on the clinical response data for the ongoing AFM24-102 phase 1/2a study in EGFRwt NSCLC.
01/08 08:00 EST - globenewswire.com
Affimed Announces Leadership Change and Organizational Restructuring
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi Hoess, Chief Executive Officer and member of the Management Board, will step down effective January 15, 2024. Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.
Affimed Announces Leadership Change and Organizational Restructuring
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi Hoess, Chief Executive Officer and member of the Management Board, will step down effective January 15, 2024. Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.
01/03 06:30 EST - globenewswire.com
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
12/19 09:08 EST - investorplace.com
3 Penny Stocks That Are Too Compelling to Ignore
While the topic of top penny stocks to buy may arouse controversy similar to apocryphal literature with spiritual implications. That might sound hyperbolic but generally, financial advisors shy away from the sector because of the extreme risks involved.
3 Penny Stocks That Are Too Compelling to Ignore
While the topic of top penny stocks to buy may arouse controversy similar to apocryphal literature with spiritual implications. That might sound hyperbolic but generally, financial advisors shy away from the sector because of the extreme risks involved.
12/11 06:02 EST - globenewswire.com
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced interim safety and efficacy data on its innate cell engager (ICE®) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy. Importantly, all patients were pretreated with and ultimately progressed while on PD-[L]1 targeting therapy.
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced interim safety and efficacy data on its innate cell engager (ICE®) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy. Importantly, all patients were pretreated with and ultimately progressed while on PD-[L]1 targeting therapy.
12/11 06:00 EST - globenewswire.com
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced updated data on its lead innate cell engager (ICE®) acimtamig. Data from the investigator-initiated trial is being presented today at the American Society of Hematology (ASH) 2023 Annual Meeting by Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and principal investigator of the study. Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig's future development.
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced updated data on its lead innate cell engager (ICE®) acimtamig. Data from the investigator-initiated trial is being presented today at the American Society of Hematology (ASH) 2023 Annual Meeting by Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and principal investigator of the study. Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig's future development.
12/04 06:30 EST - globenewswire.com
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
MANNHEIM, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on December 11 at 1:30 p.m. PST / 4:30 p.m. EST to review clinical data presented from the combination trial of acimtamig with cord-blood derived NK cells during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. During the call, the Company will also provide a clinical data update from the AFM24-102 trial.
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
MANNHEIM, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on December 11 at 1:30 p.m. PST / 4:30 p.m. EST to review clinical data presented from the combination trial of acimtamig with cord-blood derived NK cells during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. During the call, the Company will also provide a clinical data update from the AFM24-102 trial.